Journal
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
Volume 16, Issue 12, Pages 3180-3183Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmcl.2006.03.042
Keywords
renieramycin G; 3-epi-renieramycin G; jorumycin; 3-epi-jorumycin; antitumor agents; tetrahydroisoquinolines
Categories
Funding
- NCI NIH HHS [R01 CA085419-12, R01 CA085419-11, R01 CA085419, R01 CA085419-08, R01 CA085419-10, CA85419, CA105898, R01 CA085419-09, F32 CA105898] Funding Source: Medline
Ask authors/readers for more resources
Analogues of the tetrahydroisoquinoline family of antitumor antibiotics, 3-epi-jorumycin (3) and 3-epi-renieramycin G (4), in addition to their respective parent natural products (-)-jorumycin (1) and (-)-renieramycin G (2) were evaluated against both human colon (HCT-116) and human lung (A549) cancer cell lines. (-)-Jorumycin (1) displayed potent growth inhibition with GI(50) values in the low nanomolar range (1.9-24.3 nM), while compounds 2-4 were found to be substantially less cytotoxic (GI(50) 0.6-14.0 mu M). (c) 2006 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available